Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia

This publication has 56 references indexed in Scilit:

• Prospective analysis of TEL/AML1-positive patients treated on Dana-Farber Cancer Institute Consortium Protocol 95-01
  Blood, 2006
• High concordance from independent studies by the Children's Cancer Group (CCG) and Pediatric Oncology Group (POG) associating favorable prognosis with combined trisomies 4, 10, and 17 in children with NCI Standard-Risk B-precursor Acute Lymphoblastic Leukemia: a Children's Oncology Group (COG) initiative
  Leukemia, 2005
• Outcomes of a Randomized Trial of Hyperfractionated Cranial Radiation Therapy for Treatment of High-Risk Acute Lymphoblastic Leukemia: Therapeutic Efficacy and Neurotoxicity
  Journal of Clinical Oncology, 2004
• Height and Weight in Children Treated for Acute Lymphoblastic Leukemia: Relationship to CNS Treatment
  Journal of Clinical Oncology, 2003
• BFM-oriented treatment for children with acute lymphoblastic leukemia without cranial irradiation and treatment reduction for standard risk patients: results of DCLSG protocol ALL-8 (1991–1996)
  Leukemia, 2002
• CNS late‐effects after ALL therapy in childhood. Part III: Neuropsychological performance in long‐term survivors of childhood ALL: Impairments of concentration, attention, and memory*†‡
  Medical and Pediatric Oncology, 2002
• Doxorubicin Administration by Continuous Infusion Is Not Cardioprotective: The Dana-Farber 91-01 Acute Lymphoblastic Leukemia Protocol
  Journal of Clinical Oncology, 2002
• Treatment of Childhood Acute Lymphoblastic Leukemia: Results of Dana-Farber ALL Consortium Protocol 87-01
  Journal of Clinical Oncology, 2002
• Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood
  The Lancet, 1998
• Nonparametric Estimation from Incomplete Observations
  Journal of the American Statistical Association, 1958